SCHEMBL21292879

SCHEMBL21292879

O=Cc1ccc(N2CC3(COC3)C2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRIM24 O15164 1/20 0.52
TRIM33 Q9UPN9 1/20 0.52
ALDH1A1 P00352 6/20 0.50
KDM4E B2RXH2 4/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
HDAC4 P56524 1/20 0.44
MAPT P10636 1/20 0.39
ALDH3A1 P30838 1/20 0.38
ALDH1A3 P47895 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MAOB P27338 1/20 0.36
KCNJ1 P48048 1/20 0.36
MGLL Q99685 1/20 0.36
MAPK1 P28482 1/20 0.35
L3MBTL3 Q96JM7 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SYK P43405 1/20 0.34
ACHE P22303 1/20 0.34
PIK3CD O00329 1/20 0.34
PIK3CA P42336 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23043858 0.87 TRIM24 (0.50) TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2
SCHEMBL31047840 0.76 KCNJ1 (0.43) ALDH1A1KDM4EALDH3A1ALDH1A3HSD17B10
SCHEMBL30922219 0.76 KCNJ1 (0.43) HDAC4MAPTKCNJ1MGLLMAPK1
SCHEMBL17289883 0.76 HDAC4 (0.47) ALDH1A1KDM4ESMN1; SMN2HDAC4MAPT
SCHEMBL15399669 0.76 HDAC4 (0.43) ALDH1A1SMN1; SMN2HDAC4HSD17B10MGLL
SCHEMBL17308203 0.76 HDAC4 (0.43) ALDH1A1KDM4EHDAC4MAPTHSD17B10
SCHEMBL14320347 0.76 HDAC4 (0.47) ALDH1A1KDM4ESMN1; SMN2HDAC4MAPT
SCHEMBL31175173 0.75 TSHR (0.55) ALDH1A1SMN1; SMN2HDAC4HSD17B10MGLL
SCHEMBL20897576 0.74 HDAC4 (0.52) ALDH1A1KDM4EHDAC4MAPTHSD17B10
SCHEMBL211336 0.73 TRIM24 (0.70) TRIM24TRIM33ALDH1A1KDM4ESMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3759075-B1 COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE FERRO THERAPEUTICS INC (US) 2025-07-23 EP disclosed
US-20230039846-A1 COMPOUNDS AND METHODS OF USE FERRO THERAPEUTICS INC (US) 2023-02-09 US disclosed
EP-3759075-A1 COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE Ferro Therapeutics, Inc. (US) 2021-01-06 EP disclosed
US-20190263802-A1 COMPOUNDS AND METHOD OF USE MOLECULAR SKIN THERAPEUTICS, INC. 2019-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230039846-A1 COMPOUNDS AND METHODS OF USE AIFM2, GPX4, GPX1 TRIM24 4427/4885TRIM33 4752/4885ALDH1A1 1254/4885
US-20190263802-A1 COMPOUNDS AND METHOD OF USE AIFM2, GPX4, GPX1 TRIM24 4417/4885TRIM33 4792/4885ALDH1A1 1190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.